Get started
Author

Laurie E. Zyczynski

Observed names: Laura E. Zyczynski, Laurie Zyczynski
ORCID: 0000-0002-1573-407X
Observed ORCID: 0000-0002-1573-407X
OpenAlex ID: A5071012802
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma
2015 · Elizabeth J. Davis, Rashmi Chugh, et al. · European Journal of Cancer · 32
Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy
2015 · Laura E. Zyczynski, Jonathan B. McHugh, et al. · Case Reports in Oncological Medicine · 4
PDF
A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
2025 · Brittany L. Siontis, John D. Rice, et al. · Clinical Cancer Research · 2
Supplementary Table S1 from A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
2025 · Brittany L. Siontis, John D. Rice, et al.
Supplementary Table S3 from A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
2025 · Brittany L. Siontis, John D. Rice, et al.
Data from A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
2025 · Brittany L. Siontis, John D. Rice, et al.
Supplementary Table S2 from A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
2025 · Brittany L. Siontis, John D. Rice, et al.
Works count: 7
Citation count: 38
H-index: 2
I10-index: 1
Year
Topic
Type